[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Indexing Sources::
Guide for Authors::
Online Submission::
Ethics::
Articles archive::
For Reviewers::
Contact us::
::
Basic and Clinical Biochemistry and Nutrition
..
DOAJ
..
CINAHL
..
EBSCO
..
IMEMR
..
ISC
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
enamad
..
:: Volume 12, Issue 2 (Quaterly 2008) ::
Feyz 2008, 12(2): 50-54 Back to browse issues page
The Effect of Co-Trimoxazole in treatment of Toxoplasmosis Lymphadenitis
Sayed Mohammad Alavi , Leila Alavi
, alavi1329dr@yahoo.com
Abstract:   (16536 Views)

Background: Lymphadenitis is one of the clinical signs of toxoplasmosis. Co-Trimoxazole (CTM) has a good therapeutic effect on ocular and cerebral infection of T.gondii. Since this infection is epidemic in Ahvaz and due to lack of study of therapeutic effect of CTM on Toxoplasmosis Lymphadenitis (TLA), this study was carried out to determine the therapeutic effects of CTM on TLA in Ahvaz from 2005-2007.

Methods and Methods: Forty six patients with TLA were enrolled in this controlled clinical trial study. Diagnosis was based on clinical examination, serological tests (chemiluminisent) and histo-pathological examinations. Palpable lymph node, IgM>8 IU and follicular hyperplasia were defined as positive findings. The patients were randomly divided into 2 groups of 23.The test group was treated by CTM (48 mg/kg/day divided in 2 dosages) for 1 month. The control group was only observed for 1 month. The patients were followed up by physical and serological examination in month 1, 3 and 6. No palpable lymph node and IgM<6 IU were found as clinical and serological response. The data were analyzed in SPSS software using x2 test.

Results: At the end of treatment, clinical response was observed in 15 patients (65.2%) from the test group and 5 (21.7%) patients from the control group. Serological response in the test group and the control group were 52.2% and 13% respectively. There was a significant difference in therapeutic effect between two groups (p<0.05).There was no difference concerning age, sex and site of infection between the two groups (p>0.05).

Conclusion: CTM displays a good therapeutic effect on TLA and may be used in the selected patients who need treatment.

Keywords: Toxoplasmosis, Lymphadenitis, Trimethoprim-sulfamethoxazole combination
Full-Text [PDF 125 kb]   (20736 Downloads)    
Type of Study: Research | Subject: General
Received: 2008/12/22 | Revised: 2009/01/10 | Published: 2008/07/15
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alavi S M, Alavi L. The Effect of Co-Trimoxazole in treatment of Toxoplasmosis Lymphadenitis. Feyz 2008; 12 (2) :50-54
URL: http://feyz.kaums.ac.ir/article-1-639-en.html


Creative Commons License
This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.
Volume 12, Issue 2 (Quaterly 2008) Back to browse issues page
مجله علوم پزشکی فیض Feyz Medical Sciences Journal
Persian site map - English site map - Created in 0.05 seconds with 46 queries by YEKTAWEB 4645